4//SEC Filing
Rankin Aubrey 4
Accession 0001209191-22-019718
CIK 0001479290other
Filed
Mar 16, 8:00 PM ET
Accepted
Mar 17, 5:50 PM ET
Size
6.9 KB
Accession
0001209191-22-019718
Insider Transaction Report
Form 4
Rankin Aubrey
DirectorPresident, Innovation & Tech
Transactions
- Tax Payment
Common Stock
2022-03-15$15.79/sh−1,372$21,664→ 94,091 total
Holdings
- 154,302(indirect: By Trust)
Common Stock
- 321,611(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award (the "RSA") for 11,905 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Mr. Rankin's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
- [F2]These shares are held by The Rankin Irrevocable Trust. Mr. Rankin is a Trustee of the Rankin Irrevocable Trust.
- [F3]These shares are held by the Aubrey and Luanne Rankin Revocable Living Trust dated July 1, 2009. Mr. Rankin is a Trustee of this Trust.
Documents
Issuer
Revance Therapeutics, Inc.
CIK 0001479290
Entity typeother
Related Parties
1- filerCIK 0001818576
Filing Metadata
- Form type
- 4
- Filed
- Mar 16, 8:00 PM ET
- Accepted
- Mar 17, 5:50 PM ET
- Size
- 6.9 KB